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ABSTRACT 
Background: Hepatitis C virus (HCV) is one of the most common transfusion transmissible infections hence the 
introduction of routine screening for its antibodies in blood donors in most blood banks.  
Methods: This was a retrospective study in which the blood donor screening register for all intending donors 
were reviewed and analyzed. 
Results: There were 4,731 potential donors with age range 20-41years. Eighty six (1.8%) were sero-positive to 
HCV antibodies with a decreasing incidence over the period under review. The highest incidence was recorded 
the age group 31-40 years. 
Aim: To determine the sero-prevalence of HCV among blood donors in ABUTH Kaduna. 
Conclusion:  HCV infection is not uncommon in our environment hence the need to emphasize it’s routine 
screening among all potential donors.  
INTRODUCTION  
HCV is a single stranded RNA virus which until 
1989 was named non A, non B hepatitis virus, 
was responsible for 80% of post transfusion 
hepatitis  (1,2,3).  The modes of transmission are 
sexual intercourse,  accidental inoculation (as in 
intravenous drug use, tattooing, acupuncture) 
with HCV- contaminated instruments, contact 
with infected body fluids and vertical 
transmission (4,5,6).   Sickle cell disease (SCD), 
haemophilia and haemodialysis are risk factors 
due to the need for repeated        transfusion with  
blood and blood products (4, 5).  The 
seroprevalence of HCV antibodies ranges from 
1.1% to 6.7% (7) in the West African sub-region.  
 
Liver disease of variable course is the most 
common manifestation of HCV infection (4). 
Pegylated α-interferon and/or Ribavirin are used 
for the treatment of HCV with variable outcomes 
(8). 
HCV antibody screening was introduced in 
ABUTH blood bank in 1997 and since then its 
prevalence has not been determined among 
blood donors which this paper seeks to do. 
Methods: This was a hospital- based 
retrospective study.  It involved a review of the 
records of all intending blood donors on whom 
HCV antibody screening was done over a four-
year period, from January 2000 to December 
2003.  The donors were classified and analyzed 
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based on age and seropositivity.  HCV antibody 
screening was done with ELISA using Grand 
Medical Diagnostic (USA) Rapid Test kits. 
Results: There were 4,731 blood donors over the 
study period with an average of 1, 184 donors 
per year. All donors were males with an age 
range of 20-41 years. The highest seroprevalence 
for HCV was in the age group 31-40 years 
(41%).  Eighty six (1.8%) of donors were 
seropositive for HCV antibodies (Table 1).  
Table 1: HCV Seropositivity among blood donors 
Year NUMBER OF DONORS SEROPOSITIVE DONORS    (%) 
2000 914                 19                                (2) 
2001 1,425                 29                                ( 2) 
2002 970                 16                              (1.7) 
2003 1,422                 22                              (1.5) 
TOTAL 4,731                 86                              (1.8) 
 
Table 2: Age distribution of seropositive donors 
AGE GROUP                                        YEAR  
TOTAL 2000 2001 2002 20003 
≤ 20 2 3 - - 5(6%) 
21-30 7 13 8 3 31(36%) 
31-40 6 9 6 14 35(41%) 
≥41 4 4 2 5 15(17%) 
TOTAL 19 29 16 22 86(100%) 
 
Discussion: The routine screening of donors is 
essentially to ensure blood safety, particularly 
from transfusion transmissible infections such as 
HIV, HCV and HBV. The seroprevalence of 
HCV was 1.8%   however there was a gradual 
decline over the study period (Table 1). This may 
be due to Media health education on the 
prevention of viral infections especially HIV 
which share same routes of transmission with 
HCV. 
 The finding of HCV seroprevalence of 1.8% 
among blood donors in ABUTH Kaduna was 
remarkably lower than the finding by other 
workers from other parts of the country. Egah et 
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al (3) reported a HCV seroprevalence of 6% in 
Jos.  Chukwurah et al(8) in South Eastern 
Nigeria found a HCV seroprevalence of 7.6% 
while Ayolabi (10) et al (2006) in Lagos 
reported a HCV seroprevalence of 8.4% all 
among blood donors. Halim (10) et al (2000) in 
Benin reported a seroprevalence of 12.3% and 
Fasola (12) et al (2008) in Ibadan reported a 
seroprevalence of 3.9%.  The significantly lower 
prevalence in our study may be due to 
differences in the lifestyle of people in different 
regions of the country. 
 Vardas2 et al in Namibia reported a 
seroprevalence rate of 0.9% which is lower than 
our findings in Kaduna. Arthur (13) et al (1997) 
in Egypt reported 24.8% HCV seroprevalence a 
value that is significantly higher than all the 
Nigerian reports. This may be attributed to 
method the method of HCV antibody 
determination (second generation enzyme 
immunoglobulin G antibody assay by Abbot).  In 
2003 Etard et al (7) reported a seroprevalence of 
0.8% in Senegalese blood donors which is 
remarkably lower than our finding but 
comparative to the Namibian findings.   
Conclusion: The seroprevelance of HCV was 
1.8% and was more prevalent amongst the 31-
40yrs age group. There is a need for mandatory 
screening for HCV antibodies in all blood banks 
and for continuous health education of the donor 
population in order to ensure the availability of 
safe blood. 
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